Everything below concerns Thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
=== New Zealand === Beak trimming, officially known as 'beak tipping' in law, is legal but regulated in New Zealand. The Layer Hens Code of Welfare (last updated 1 October 2018) notes that the National Animal Welfare Advisory Committee (NAWAC) "encourages the industry to develop management systems to protect against all forms of injurious pecking without the need for beak tipping". The Code recommends that "[a]lternative strategies for managing injurious (feather) pecking that minimise the need for beak tipping should be employed e.g. use and availability of different foraging resources." In case that beak tipping is deemed necessary, however, it requires competent trained operators, must be carried out within 3 days of hatching (except in emergencies under veterinary supervision) and may not remove more than one-quarter of the upper or lower beaks.
For example, in the figure showing trypanothione reductase from the human protozoan parasite Trypanosoma cruzi, two molecules of an inhibitor called quinacrine mustard are bound in its active site. The top molecule is bound reversibly, but the lower one is bound covalently as it has reacted with an amino acid residue through its nitrogen mustard group.
== Tolerance and overdoses == Fatal opioid overdose typically occurs due to bradypnea, hypoxemia, and decreased cardiac output (hypotension occurs due to vasodilation, and bradycardia further contributes to decreased cardiac output). A potentiation effect occurs when opioids are combined with ethanol, benzodiazepines, barbiturates, or other central depressants which can result in rapid loss of consciousness and an increased risk of fatal overdose. Substantial tolerance to respiratory depression develops quickly, and tolerant individuals can withstand larger doses. However, tolerance to respiratory depression is quickly lost during withdrawal and may be completely reversed within a week. Many overdoses occur in people who return to their previous dose after having lost their tolerance following cessation of opioids. This puts addicts who receive medical treatment for opioid addiction at great risk of overdose when they are released, as they may be particularly vulnerable to relapse. Less commonly, massive overdoses have been known to cause circulatory collapse from vasodilation and bradycardia. Opioid overdoses can be rapidly reversed through the use of opioid antagonists, naloxone being the most widely used example. Opioid antagonists work by binding competitively to μ-opioid receptors and displacing opioid agonists. Additional doses of naloxone may be necessary and supportive care should be given to prevent hypoxic brain injury by monitoring vital signs.
== The role of specific tissues and organs in transamination == Transamination takes place in several tissues and organs, especially the liver and skeletal muscle, which work together to manage amino groups generated during amino acid catabolism. The liver is the primary site of transamination. After proteins are digested into their monomers, amino acids, these amino acids are transported to the liver. In the cytoplasm of hepatocytes, the amino groups from many amino acids are transferred to α-ketoglutarate, forming glutamate in a transamination reaction. Through this process the amino groups from different amino acids are combined into glutamate, reducing the need for multiple enzymes in subsequent elimination or biosynthetic processes. After this transamination reaction, glutamate is transported into the mitochondria, where glutamate dehydrogenase catalyzes an oxidative deamination reaction, releasing ammonium. Free ammonium is toxic to cells, so the liver rapidly converts it to carbamoyl phosphate through a reaction with bicarbonate, allowing it to enter the urea cycle for excretion. The liver also contains aspartate aminotransferase. This enzyme catalyzes a unique reaction where oxaloacetate, instead of α-ketoglutarate, serves as the amino-group acceptor. In this reaction, glutamate transfers an amino group to oxaloacetate, forming the amino acid aspartate and regenerating α-ketoglutarate. Aspartate can then enter the urea cycle, where it combines with citrulline. Skeletal muscles is another site of transamination.
Sources: en.wikipedia.org
=== Fl–Fu === Louis B. Flexner (1902–1996). American biochemist at the University of Pennsylvania, who worked on the biochemistry of memory and brain function. Member Natl. Acad. Sci. USA. Otto Folin (1867–1934). Swedish-American chemist at Harvard, best known for developing methods for the determination of the constituents of protein-free blood filtrates. Member Natl. Acad. Sci. USA. Karl August Folkers (1906–1997). American biochemist at Merck, known for work on the antibiotics cathomycin and cycloserine. Ivar Asbjørn Følling (1888–1973). Norwegian biochemist and geneticist who first described phenylketonuria. Sidney W. Fox (1912–1998). American biochemist at the University of Miami who worked on the production of amino acids in abiotic conditions. Heinz Fraenkel-Conrat (1910–1999). German-American biochemist at UC Berkeley, known for research on viruses such as tobacco mosaic virus. Member Natl. Acad. Sci. USA. Rosalind Franklin (1920–1958). British X-ray crystallographer at King's and Birkbeck Colleges, London, who worked on the structure of DNA Perry A. Frey (b. 1935). American biochemist at the University of Wisconsin known for work on enzyme mechanisms. Member Natl. Acad. Sci. USA. Irwin Fridovich (1929–2019). American biochemist at Duke University, who discovered superoxide dismutase and studied its mechanisms and superoxide toxicity. Member Natl. Acad. Sci. USA. Joseph S. Fruton (1912–2007). Polish-American biochemist at the Rockefeller Institute.
Their isotopic signatures indicate that they grew up in a temperate environment consuming mostly C3 plants, but some C4 The study argued that these individuals were from the Indian Ocean area. It also suggested that these individuals were Muslims. It argued that stable isotopic analysis of burials, combined with historical and archaeological data were an effective way of investigating the migrations forced by the African Slave Trade, as well as the emergence of the underclass and working class in the Old World.
=== Use of methylene chloride === Merck & Co. once used methylene chloride, a "priority pollutant" on the United States Environmental Protection Agency's list of pollutants and an animal carcinogen. It was used as a solvent in the manufacturing process for imipenem, an ingredient of the antibiotic Primaxin. Merck chemists and engineers subsequently replaced the compound with others having fewer negative environmental effects. Merck has also modified its equipment to provide greater control over its manufacturing process. Biological oxygen demand was reduced by 75%.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.